No abstract available
Keywords:
Angioimmunoblastic T-cell lymphoma; Complete response; Lenalidomide; Splenomegaly; Vascular-endothelial growth factor.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Female
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunoblastic Lymphadenopathy / diagnosis
-
Immunoblastic Lymphadenopathy / drug therapy*
-
Immunoblastic Lymphadenopathy / pathology*
-
Lenalidomide
-
Lymph Nodes / pathology
-
Lymphoma, T-Cell / diagnosis
-
Lymphoma, T-Cell / drug therapy*
-
Lymphoma, T-Cell / pathology*
-
Middle Aged
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Positron-Emission Tomography
-
Prednisone / therapeutic use
-
Recurrence
-
Retreatment
-
Thalidomide / analogs & derivatives*
-
Thalidomide / therapeutic use
-
Tomography, X-Ray Computed
-
Transplantation, Autologous
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Thalidomide
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Lenalidomide
-
Prednisone